The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
The tumor microenvironment is a dominant force in multidrug resistance
Open accessAbstract
The emergence of clinical drug resistance is still one of the most challenging factors in cancer treatment effectiveness. Until more recently, the assumption has been that random genetic lesions are sufficient to explain the progression of malignancy and escape from chemotherapy. Here we propose an additional perspective, one in which the tumor cells despite the malignant genome could find a microenvironment either within the tumor or as a dormant cell to remain polar and blend into an organized context. Targeting this dynamic interplay could be considered a new avenue to prevent therapeutic resistance, and may even provide a promising effective cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Tissue Cells Feel and Respond to the Stiffness of Their Substrate
Discher, D. E., Janmey, P., & Wang, Y.-L. (2005) · Science · doi:10.1126/science.1116995 · Cited by 6,382
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Tensional homeostasis and the malignant phenotype
Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., Reinhart-King, C. A., Margulies, S. S., Dembo, M., Boettiger, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.010 · Cited by 3,941
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion
Yeung, T., Georges, P. C., Flanagan, L. A., Marg, B., Ortiz, M., Funaki, M., Zahir, N., Ming, W., Weaver, V., & Janmey, P. A. (2005) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.20041 · Cited by 2,325
Cited by
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
3D tumor spheroids: an overview on the tools and techniques used for their analysis
Costa, E. C., Moreira, A. F., de Melo-Diogo, D., Gaspar, V. M., Carvalho, M. P., & Correia, I. J. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.11.002 · Cited by 929
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 771
Nunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F., & Correia, I. J. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26845 · Cited by 721
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Impact of the physical microenvironment on tumor progression and metastasis
Spill, F., Reynolds, D. S., Kamm, R. D., & Zaman, M. H. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.007 · Cited by 581
Three-dimensional in vitro tumor models for cancer research and drug evaluation
Xu, X., Farach-Carson, M. C., & Jia, X. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.07.009 · Cited by 461
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S.-H., & Chang, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 428
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403
“by decreasing drug concentrations through increased interstitial fluid pressure, 3D structure or by activating cellular pathways through ECM-Integrin binding, the so-called cell adhesion-mediated drug resistance (CAM-DR) [78].”
BackgroundHickman, J. A., Graeser, R., de Hoogt, R., Vidic, S., Brito, C., Gutekunst, M., van der Kuip, H., & IMI PREDECT consortium (2014) · Biotechnology Journal · doi:10.1002/biot.201300492 · Cited by 380
Cancer associated fibroblasts: An essential role in the tumor microenvironment
Tao, L., Huang, G., Song, H., Chen, Y., & Chen, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6497 · Cited by 351
Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy
Correia, A. L., Guimaraes, J. C., Auf der Maur, P., De Silva, D., Trefny, M. P., Okamoto, R., Bruno, S., Schmidt, A., Mertz, K., Volkmann, K., et al. (2021) · Nature · doi:10.1038/s41586-021-03614-z · Cited by 339
Self-citationWeigelt, B., Ghajar, C. M., & Bissell, M. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.001 · Cited by 335
Self-citationEmerging roles of ECM remodeling processes in cancer
Mohan, V., Das, A., & Sagi, I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.004 · Cited by 334
The role of tumor microenvironment in therapeutic resistance
Son, B., Lee, S., Youn, H., Kim, E., Kim, W., & Youn, B. (2017) · Oncotarget · doi:10.18632/oncotarget.13907 · Cited by 300
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
Guerriero, J. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.006 · Cited by 293
Hu, K., Miao, L., Goodwin, T. J., Li, J., Liu, Q., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01522 · Cited by 292
Castells, M., Thibault, B., Delord, J.-P., & Couderc, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 285
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Modeling neoplastic disease with spheroids and organoids
Zanoni, M., Cortesi, M., Zamagni, A., Arienti, C., Pignatta, S., & Tesei, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00931-0 · Cited by 261
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Mhaidly, R., & Mechta-Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 259
Mhaidly, R., & Mechta‐Grigoriou, F. (2021) · Immunological Reviews · doi:10.1111/imr.12978 · Cited by 231
Design of spherically structured 3D in vitro tumor models -Advances and prospects
Ferreira, L. P., Gaspar, V. M., & Mano, J. F. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.034 · Cited by 249
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
“On one hand, increases in matrix stiffness are likely to induce transformation of mammary epithelial cells [17].”
BackgroundEmerging tumor spheroids technologies for 3D in vitro cancer modeling
Rodrigues, T., Kundu, B., Silva-Correia, J., Kundu, S. C., Oliveira, J. M., Reis, R. L., & Correlo, V. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.018 · Cited by 178
3D Bioprinting of Breast Cancer Models for Drug Resistance Study
Wang, Y., Shi, W., Kuss, M., Mirza, S., Qi, D., Krasnoslobodtsev, A., Zeng, J., Band, H., Band, V., & Duan, B. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01277 · Cited by 157
Hachey, S. J., Movsesyan, S., Nguyen, Q. H., Burton-Sojo, G., Tankazyan, A., Wu, J., Hoang, T., Zhao, D., Wang, S., Hatch, M. M., et al. (2021) · Lab on a Chip · doi:10.1039/d0lc01216e · Cited by 124
Applications of tumor chip technology
Hachey, S. J., & Hughes, C. C. W. (2018) · Lab on a Chip · doi:10.1039/c8lc00330k · Cited by 128
Impact of the spheroid model complexity on drug response
Hoffmann, O. I., Ilmberger, C., Magosch, S., Joka, M., Jauch, K.-W., & Mayer, B. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.02.029 · Cited by 125
Niu, Y., Lin, Z., Wan, A., Sun, L., Yan, S., Liang, H., Zhan, S., Chen, D., Bu, X., Liu, P., et al. (2021) · Hepatology · doi:10.1002/hep.31846 · Cited by 115
Ramamonjisoa, N., & Ackerstaff, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00003 · Cited by 93
Cellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Liquid-based three-dimensional tumor models for cancer research and drug discovery
Ham, S. L., Joshi, R., Thakuri, P. S., & Tavana, H. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216643772 · Cited by 91
Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy
Muntimadugu, E., Kommineni, N., & Khan, W. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.010 · Cited by 82
Proteinaceous Hydrogels for Bioengineering Advanced 3D Tumor Models
Blanco‐Fernandez, B., Gaspar, V. M., Engel, E., & Mano, J. F. (2021) · Advanced Science · doi:10.1002/advs.202003129 · Cited by 78
Boudreau, A., van't Veer, L. J., & Bissell, M. J. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20880 · Cited by 43
Self-citationAnti-tumour effects of all-trans retinoid acid on serous ovarian cancer
Lokman, N. A., Ho, R., Gunasegaran, K., Bonner, W. M., Oehler, M. K., & Ricciardelli, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1017-7 · Cited by 39
Metadata
- Authors
- Correia, A. L., & Bissell, M. J.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 15
- Issue
- 1-2
- Pages
- 39-49
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2002906517
- Cited by
- 443
- References
- 160
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.